Patients with clinically isolated syndromes (CIS) are prone to develop multiple sclerosis (MS). The randomized, placebo-controlled CHAMPS trial found early treatment with interferon -1a to be ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways MS medications can help slow the disease and manage symptoms.

Disease-Modifying Therapy Comparison and Side Effects ...

Rebif is a brand-name liquid solution that’s typically self-injected. It’s prescribed for certain forms of multiple sclerosis (MS) and contains the active ingredient interferon beta-1a. It is not ...

MS typically appears in young adulthood, but 3% to 5% of cases have an onset in early childhood or adolescence. No disease-modifying therapies have FDA approval for persons younger than 18 years of ...